Fizazi reports the phase 2 A-DREAM trial, where patients with dramatic responses after 18–24 months of ADT and at least a year of an AR pathway inhibitor stopped treatment. About 40% were treatment-free and eugonadal at 18 months, with a median roughly two years before progression. Formal phase 3 testing is ongoing.
Fizazi criticizes PROTEASE's control arm because it was not surgery alone; both arms received neoadjuvant ADT, which drives postoperative PSA to zero. That prevents clinicians from using PSA to trigger adjuvant radiation or intensification, a key limitation for translating the trial into practice. He calls this a design criticism.
In TALAPRO-3, adding talazoparib to ADT plus enzalutamide in de novo metastatic hormone-sensitive prostate cancer with DNA repair alterations sharply improved radiographic progression-free survival. Fizazi says the benefit appears across alterations, including BRCA2 and biallelic CDK12, though gene-by-gene homework remains. He also sees an overall survival signal, but final analysis is pending.
Fizazi says PROTEASE was positive for metastasis-free survival only after investigators amended the protocol to include PSMA PET; the original conventional-imaging endpoint had a p-value above 0.05. That split interpretation—positive by amended endpoint, not by original—fuels debate about whether to intensify high-risk localized disease. He notes opinions remain divided among clinicians.
Fizazi notes PSMAfore improved radiographic progression-free survival with a hazard ratio of 0.5, yet showed no overall survival benefit because most control patients crossed over to lutetium PSMA, often progressing within six months. He frames the comparison as immediate versus deferred radioligand therapy. Quality-of-life and symptomatic progression still favored treatment.
Fizazi explains that under hormonal pressure, androgen receptor mutations can let progesterone, prednisone, or estrogens stimulate prostate cancer. Opevesostat blocks CYP11, the first enzyme downstream of cholesterol, suppressing all steroid hormones; patients need glucocorticoid and mineralocorticoid replacement, and OMAR trials are testing it before and after docetaxel.
